Are there specific gram positive bacteria strains resistant to tigecycline?

Are there specific gram positive bacteria strains resistant to tigecycline?

Why do gram positive bacteria develop resistance to tigecycline?

Gram positive bacteria can develop resistance through efflux pumps encoded by tet genes such as tet(K), tet(L), and tet(M). These pumps expel the glycylcycline from the ribosomal binding site, rendering the drug ineffective. Some gram positive strains also modify the ribosome itself, preventing tigecycline from binding properly.

How does this resistance compare across common gram positive species?

Enterococcus faecalis and Enterococcus faecium show resistance rates ranging from 0.5% to 5% in recent surveillance data. Staphylococcus aureus isolates exhibit rates from 0.1% to 3%, especially among methicillin-resistant strains. Streptococcus pneumoniae isolates rarely show resistance, but a few clinical isolates with tet(M) genes have been reported.

When did tigecycline resistance emerge and how does it emerge?

Resistance reports began appearing in 2005, shortly after tigecycline launch. It emerges either horizontally through plasmid-mediated tet genes or vertically through spontaneous mutations that raise MICs tenfold or higher. Recent isolates from intensive care units show rising MIC90 values, rising from 0.25 mg/L to 0.5 mg/L over the last decade.

Can patients pick up resistant gram positive bacteria in hospitals?

Yes. Hospital environments serve as reservoirs for resistant Enterococcus and Staphylococcus strains. Patients with prolonged stays, multiple courses of antibiotics, or use of central lines are at higher risk. Surveillance programs tracking tigecycline susceptibility in ICUs show higher rates of non-susceptible isolates in these settings.

What alternatives exist if gram positive bacteria show tigecycline resistance?

Linezolid, daptomycin, and vancomycin remain effective against most tigecycline-resistant gram positive strains. Vancomycin-resistant Enterococcus has shown increased reliance on linezolid and daptomycin, but some isolates now show dual resistance. Daptomycin non-susceptible strains require susceptibility testing before use.

Who manufactures tigecycline and who owns its patents?

Tigecycline is manufactured by Pfizer. The primary compound patent expired in 2010. Secondary patents covering formulations and salt forms have extended exclusivity into 2023 in some regions. [1]

When does tigecycline's patent expire?

The main compound patent expired in 2010. Secondary patents on formulations cover until 2023.